648422-57-5

Upstream product

• 630-19-3 pivalaldehyde 
• 302840-64-8 (2R)-2-amino-N-(3,5-dichlorophenyl)-propionamide 
• 626-43-7 3,5-Dichloroaniline 
• 302840-63-7 (1R)-[1-(3,5-dichloro-phenylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester 

Downstream Products

• 321724-17-8 (2S,5R)-2-tert-butyl-3-(3,5-dichlorophenyl)-5-methyl-1-trifluoroacetyl-imidazolidin-4-one 
• 302840-64-8 (2R)-2-amino-N-(3,5-dichlorophenyl)-propionamide 
• 302840-67-1 (2R)-2-amino-3-(4-bromophenyl)-N-(3,5-dichlorophenyl)-2-methyl-propionamide 
• 213208-73-2 (5R)-5-(4-bromobenzyl)-3-(3,5-dichlorophenyl)-5-methyl-1H-imidazole-2,4(3H,5H)-dione 
• 648422-58-6 (2R,5R)-5-(4-bromo-benzyl)-2-tert-butyl-3-(3,5-dichlorophenyl)-5-methyl-1-trifluoroacetyl-imidazolin-4-one 

Relevant academic research and scientific papers

Practical synthesis of a cell adhesion inhibitor by self-regeneration of stereocenters

An efficient enantiospecific synthesis of the cell adhesion inhibitor BIRT-377 by self-regeneration of stereocenters has been achieved in 38% overall yield in eight steps. The key transformations involve the stereoselective formation of the trans imidazol

Self-regeneration of stereocenters: A practical enantiospecific synthesis of LFA-1 antagonist BIRT-377

An efficient enantiospecific synthesis of the LFA-1 antagonist BIRT-377 has been achieved in 43percent overall yield in eight steps. The key transformations involve the stereospecific formation of the trans imidazolidinone 7, subsequent alkylation, and th